Novocure, an oncology company, has signed a long term supply contract with ITT Electronic Systems for the supply of piezoelectric ceramic components, which are used in the manufacture of disposable electrodes.
These electrodes will be used in the NovoTTF-100A System, which is approved by the FDA as a device for the treatment of adult patients suffering from recurring glioblastoma brain tumors (GBM).
Mike Ambrogi, who is the COO of Novocure, has remarked that the NovoTTF-100A System was a therapeutic medical equipment that will perform time and again inside set operating parameters. ITT’s piezoelectric ceramic electrode sensing technology adapted from a military application completely met the exacting technical specifications.
This system includes ITT’s disposable electrodes and other accessories along with an electronic field generator. The disposable electrodes contain high tolerance sensors, which would guarantee that the Novo system will provide electric fields for targeting tissues within safe and effective parameters, and thus thwart or avoid transmission of electric currents. These electrodes are made use of by patients for several days and then thrown away and replaced by new ones.
Source: http://www.novocure.com